Strengths

AstraZeneca’s diversified oncology, rare disease, and cardiovascular franchises support durable demand breadth versus narrower peers, reducing dependence on any single therapeutic cycle.

The company’s TTM ROIC of 12.7% indicates solid capital efficiency, comparing favorably with many large-cap pharma peers that typically struggle to sustain double-digit returns.

Its deeply negative cash conversion cycle of -365.3 days reflects strong working-capital dynamics and customer-funded operations, which structurally support liquidity versus peers with longer cash cycles.

A broad global commercial footprint and late-stage pipeline depth strengthen launch optionality, helping AZN compete more effectively than smaller biopharma peers in multiple therapeutic areas.

Weaknesses

Net debt to EBITDA of 1.34x leaves AZN more levered than the strongest cash-rich peers, limiting balance-sheet flexibility in a capital-intensive industry.

The current ratio of 0.89x and quick ratio of 0.67x indicate weaker near-term liquidity than peers with larger cash buffers, despite strong operating cash generation.

Dependence on patent-protected products creates eventual exclusivity risk, leaving AZN exposed to revenue erosion similar to other large pharma peers when key assets mature.

Reported margin data are unavailable here, but the company’s scale and R&D intensity imply ongoing pressure to defend profitability against larger diversified peers and lower-cost competitors.

Opportunities

Pipeline conversion in oncology and rare disease can expand AZN’s addressable market, and successful launches would likely outgrow peers with less differentiated late-stage assets.

Lifecycle management and label expansion can extend franchise duration, improving revenue durability versus peers that rely more heavily on single-indication products.

Geographic expansion in emerging markets offers incremental demand growth, where AZN’s global reach can outcompete smaller peers with limited commercial infrastructure.

Continued capital deployment into high-return assets could compound ROIC, allowing AZN to widen its structural advantage over peers with weaker reinvestment efficiency.

Threats

Patent expirations and biosimilar competition can compress revenue and margins, a structural threat shared with peers but especially material for large branded pharma portfolios.

Pricing pressure from payers and governments can limit realized growth, and AZN faces the same reimbursement scrutiny as other multinational pharmaceutical companies.

Clinical trial setbacks or regulatory delays can impair pipeline value, making AZN’s future growth more dependent on execution than peers with already-mature cash flows.

Higher leverage than the strongest peers reduces resilience if growth slows, because refinancing and capital-allocation constraints become more binding in a downturn.

Overall Score

AZN is structurally strong versus peers, anchored by diversified demand, solid capital efficiency, and pipeline depth, though leverage and liquidity remain moderate constraints.